Zura Bio Ltd (ZURA)

Currency in USD
3.930
-0.170(-4.15%)
Closed·
4.120+0.190(+4.83%)
·
ZURA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ZURA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.8604.210
52 wk Range
0.9705.070
Key Statistics
Prev. Close
4.1
Open
4
Day's Range
3.86-4.21
52 wk Range
0.97-5.07
Volume
973.2K
Average Volume (3m)
1.64M
1-Year Change
-10.27%
Book Value / Share
2.03
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ZURA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.333
Upside
+239.27%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Zura Bio Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Zura Bio Ltd Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.

Compare ZURA to Peers and Sector

Metrics to compare
ZURA
Peers
Sector
Relationship
P/E Ratio
−3.9x−4.9x−0.6x
PEG Ratio
0.100.020.00
Price/Book
2.0x2.4x2.6x
Price / LTM Sales
-10.2x3.4x
Upside (Analyst Target)
230.8%122.9%35.5%
Fair Value Upside
Unlock−2.8%3.7%Unlock

Analyst Ratings

6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 13.333
(+239.27% Upside)

Earnings

Latest Release
Aug 14, 2025
EPS / Forecast
-0.17 / -0.30
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ZURA Income Statement

People Also Watch

27.28
HRMY
+1.94%
84.16
AMBA
-2.28%
63.80
HNKG
+0.31%
9.040
LAC
+31.78%
17.910
USAU
+8.28%

FAQ

What Stock Exchange Does Zura Bio Ltd Trade On?

Zura Bio Ltd is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Zura Bio Ltd?

The stock symbol for Zura Bio Ltd is "ZURA."

What Is the Zura Bio Ltd Market Cap?

As of today, Zura Bio Ltd market cap is 255.52M.

What Is Zura Bio Ltd's Earnings Per Share (TTM)?

The Zura Bio Ltd EPS (TTM) is -0.72.

From a Technical Analysis Perspective, Is ZURA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Zura Bio Ltd Stock Split?

Zura Bio Ltd has split 0 times.

How Many Employees Does Zura Bio Ltd Have?

Zura Bio Ltd has 0 employees.

What is the current trading status of Zura Bio Ltd (ZURA)?

As of 05 Oct 2025, Zura Bio Ltd (ZURA) is trading at a price of 3.930, with a previous close of 4.10. The stock has fluctuated within a day range of 3.860 to 4.210, while its 52-week range spans from 0.970 to 5.070.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.